Background
Trichomoniasis is a sexually transmitted infection caused by the protozoa Trichomonas vaginalis. It is one of the most common sexually transmitted diseases in the United States.[1] Trichomoniasis in women may be asymptomatic or may cause various symptoms, including a frothy yellow-green vaginal discharge and vulvar irritation. Men with trichomoniasis are frequently asymptomatic.[2]
The high incidence of T vaginalis infection worldwide and coinfection with other sexually transmitted infections make trichomoniasis a compelling public health concern. Notably, T vaginalis infection is believed to increase the risk of HIV transmission.[1] Trichomoniasis is also associated with adverse pregnancy outcomes, infertility, postoperative infections, and cervical neoplasia.[3]
In addition to the sexually transmitted species T vaginalis, other rarer Trichomonas species are occasionally observed in the mouth and in lung samples. These species are usually found in immunocompromised patients, most notably those with underlying lung cancer.
Pathophysiology
T vaginalis is approximately the size of a white blood cell (about 10 μm in diameter), although its size may vary with physical conditions. Its flagellum allows it to move around vaginal and urethral tissues. T vaginalis directly damages the epithelium, leading to microulcerations of inhabited tissues, increasing the risk of HIV transmission.[1]
Symptoms of trichomoniasis typically occur after an incubation period of 4-28 days. In women, T vaginalis is isolated from the vagina, cervix, urethra, bladder, and Bartholin and Skene glands. In men, the organism is found in the anterior urethra, external genitalia, prostate, epididymis, and semen.
Epidemiology
Frequency
United States
Approximately 8 million new cases of trichomoniasis occur annually.[4] The prevalence of T vaginalis infection at clinics that treat STDs varies from 15-54%.[5] In men, trichomoniasis accounts for 10-21% of urethritis cases not attributable to gonorrheal or chlamydial infection.[5]
In considering risk factors for prevalent trichomoniasis, drug use in the preceding 30 days was most associated with infection and with incident infection (new infection observed during the study). The most significant risk factor was sexual behavior in the preceding 30 days (with one or more partners). Women with one or more sexual partners in the preceding 30 days were 4 times more likely to acquire T vaginalis infection.[6]
International
Worldwide, the annual incidence of trichomoniasis is about 170 million cases.[7] The incidence of trichomoniasis in Europe is similar to that in the United States. In Africa, the prevalence of trichomoniasis may be much higher.
Mortality/Morbidity
T vaginalis infection is highly associated with the presence of other sexually transmitted infections, including gonorrhea, chlamydia, and sexually transmitted viruses. T vaginalis infection increases the susceptibility to others viruses, including herpes, human papillomavirus (HPV), and HIV.[8] Persons with trichomoniasis are twice as likely to develop HIV infection as the general population.[9] Two explanations exist for the association between T vaginalis and HIV: (1) Disruption of the epithelial monolayer leads to increased passage of the HIV virus; (2) T vaginalis induces immune activation, specifically lymphocyte activation and replication and cytokine production, leading to increased viral replication in HIV-infected cells.
Pregnant women with T vaginalis infection are more likely than uninfected women to deliver preterm or to have other adverse pregnancy outcomes, including low birth weight, premature rupture of membranes, and intrauterine infection.[1] However, whether trichomoniasis causes the adverse outcome is unclear.[1]T vaginalis infection may also increase the transmission of HIV owing to a disruption of the vaginal mucosa. Respiratory or genital infection in the newborn should also be considered.[2]
One study reported a higher risk of pelvic inflammatory disease in women with trichomoniasis.[10] Other studies have reported a 1.9-fold risk of tubal infertility in women with trichomoniasis.[11] Trichomoniasis may also play a role in cervical neoplasia and postoperative infections.[3]
In men, complications of untreated trichomoniasis include prostatitis, epididymitis, urethral stricture disease, and infertility. Infertility may result from a decreased sperm motility and viability.[3]
See the Clinical section for presenting symptoms and signs.
Race
Evidence suggests that T vaginalis infection most likely increases HIV transmission. Thus, the observed higher prevalence of T vaginalis infection in African Americans is cause for concern. Although T vaginalis may increase the risk of HIV transmission by only a small to moderate amount, its high prevalence in the African American community makes it a cause of measurable increase in rates of HIV transmission. Therefore, control of T vaginalis may represent an important means of slowing HIV transmission, particularly among African Americans.[12]
Sex
Symptomatic trichomoniasis is more common in women than in men. Trichomoniasis infection in men is less clinically apparent.
Age
Trichomoniasis is a sexually transmitted infection. As such, it is typically found in sexually active adolescents and adults. In female adolescents, trichomoniasis is more common than gonorrhea; this is particularly disconcerting since it increases the susceptibility to other viruses.[8]
Forna F, Gülmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev. 2003;CD000218. [Medline].
[Guideline] Centers for Disease Control and Prevention (CDC), Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. Aug 4 2006;55:1-94. [Medline].
Soper D. Trichomoniasis: under control or undercontrolled?. Am J Obstet Gynecol. Jan 2004;190(1):281-90. [Medline].
Gerbase AC, Rowley JT, Mertens TE. Global epidemiology of sexually transmitted diseases. Lancet. 1998;351 Suppl 3:2-4. [Medline].
Sobel JD. What's new in bacterial vaginosis and trichomoniasis?. Infect Dis Clin North Am. Jun 2005;19(2):387-406. [Medline].
Miller M, Liao Y, Gomez AM, Gaydos CA, D'Mellow D. Factors associated with the prevalence and incidence of Trichomonas vaginalis infection among African American women in New York city who use drugs. J Infect Dis. Feb 15 2008;197(4):503-9. [Medline].
Patel SR, Wiese W, Patel SC, Ohl C, Byrd JC, Estrada CA. Systematic review of diagnostic tests for vaginal trichomoniasis. Infect Dis Obstet Gynecol. 2000;8(5-6):248-57. [Medline].
Huppert JS. Trichomoniasis in teens: an update. Curr Opin Obstet Gynecol. Oct 2009;21(5):371-8. [Medline].
Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS. Jan 1993;7(1):95-102. [Medline].
Moodley P, Wilkinson D, Connolly C, et al. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis. Feb 15 2002;34(4):519-22. [Medline].
Grodstein F, Goldman MB, Ryan L, et al. Relation of female infertility to consumption of caffeinated beverages. Am J Epidemiol. Jun 15 1993;137(12):1353-60. [Medline].
Shafir SC, Sorvillo FJ, Smith L. Current issues and considerations regarding trichomoniasis and human immunodeficiency virus in African-Americans. Clin Microbiol Rev. Jan 2009;22(1):37-45, Table of Contents. [Medline].
Mann JR, McDermott S, Zhou L, Barnes TL, Hardin J. Treatment of trichomoniasis in pregnancy and preterm birth: an observational study. J Womens Health (Larchmt). Apr 2009;18(4):493-7. [Medline].
[Guideline] ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists, Number 72, May 2006: Vaginitis. Obstet Gynecol. May 2006;107(5):1195-1206. [Medline].
Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol. Feb 1995;172(2 Pt 1):525-9. [Medline].
Guenthner PC, Secor WE, Dezzutti CS. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect Immun. Jul 2005;73(7):4155-60. [Medline]. [Full Text].
Nanda N, Michel RG, Kurdgelashvili G, et al. Trichomoniasis and its treatment. Expert Rev Anti Infect Ther. Feb 2006;4(1):125-35. [Medline].
Radonjic IV, Dzamic AM, Mitrovic SM, Arsic Arsenijevic VS, Popadic DM, Kranjcic Zec IF. Diagnosis of Trichomonas vaginalis infection: The sensitivities and specificities of microscopy, culture and PCR assay. Eur J Obstet Gynecol Reprod Biol. May 1 2006;126(1):116-20. [Medline].

